Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 15/20 | 0.42 |
| ▸ | TOP1 | P11387 | 8/20 | 0.42 |
| ▸ | TOP2B | Q02880 | 8/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19728610 | 0.91 | TOP2A (0.43) | TOP2ATOP1TOP2BCYP3A4CYP2C9 | |
| SCHEMBL19728748 | 0.91 | CYP3A4 (0.50) | TOP2ATOP1TOP2BCYP3A4CYP2C9 | |
| SCHEMBL19728716 | 0.90 | TOP2A (0.42) | TOP2ATOP1TOP2BCYP3A4CYP2C9 | |
| SCHEMBL19729060 | 0.89 | TOP2A (0.42) | TOP2ATOP1TOP2BCYP3A4CYP2C9 | |
| SCHEMBL19729352 | 0.88 | TOP2A (0.46) | TOP2ATOP1TOP2BCYP3A4CYP2C9 | |
| SCHEMBL19728351 | 0.88 | TOP2A (0.51) | TOP2ATOP1TOP2BCYP3A4CYP2C9 | |
| SCHEMBL19728729 | 0.86 | TOP2A (0.46) | TOP2ATOP1TOP2B | |
| SCHEMBL19728763 | 0.84 | TOP2A (0.45) | TOP2ATOP1TOP2BKCNH2 | |
| SCHEMBL20912595 | 0.84 | TOP2A (0.43) | TOP2ATOP1TOP2BCYP3A4CYP2C9 | |
| SCHEMBL19728609 | 0.83 | TOP2A (0.60) | TOP2ATOP1TOP2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190276407-A1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2019-09-12 | — | — | US | disclosed |
| US-20190276407-A1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2019-09-12 | — | — | US | disclosed |
| EP-3473616-A1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | Wakunaga Pharmaceutical Co., Ltd. (JP) | 2019-04-24 | — | — | EP | disclosed |
| WO-2017217441-A1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | 湧永製薬株式会社 | 2017-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190276407-A1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | CTR9, PYCR1, ACAD9 | TOP2A 4246/4885TOP1 3571/4885TOP2B 4085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.